Climb Bio, Inc.

Healthcare · Biotechnology · United States

Last price 10.25 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 588.72M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ...